SCIENTIFIC PROGRAM

as of November, 2025

 

WEDNESDAY, NOVEMBER 12, 2025

08:00 AM – 11:00 AM Pre-meeting IEC Symposium
09:00 AM – 02:00 PM Symposium on Malignant Skin inflammation
02:00 PM – 03:00 PM Sponsored Pre-Meeting Symposium I.
03:15 PM – 04:15 PM Sponsored Pre-Meeting Symposium II.

 

04:30 PM – 04:45 PM Welcome Address by the Organizing Committee
04:45 PM – 05:15 PM Keynote Lecture (Miriam Merad, New York, USA)
05:15 PM – 06:00 PM Oral Presentations from Selected Abstracts

  • JAK3/TEC Inhibition is Safe and Effective in Cicatricial Alopecias: Results from a Prospective Trial (Anusha Pasumarthi, New York, USA)
  • Anti-IL-15 treatment results in greater repigmentation in vitiligo than placebo in participants who receive phototherapy and reduces circulating terminally differentiated cytotoxic CD8 memory cells (Laura Cooney, Ann Arbor, USA)

  • Improvement of Skin Transcriptome and Pruritus within 24 Hours with Topical Triamcinolone in Atopic Dermatitis: A Randomized, Vehicle-Controlled Study (Robert Bissonnette, Montral, Canada)

  • Efficacy and Safety of Brepocitinib in Patients with Active Dermatomyositis: Results from a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase III (VALOR) Trial (Alisa Femia, New York, USA)
06:00 PM – 06:30 PM Decoding mechanisms of skin inflammation (Shruti Naik, New York, USA)
06:30 PM – 07:30 PM Sponsored Dinner Symposium
07:30 PM – 10:00 PM Welcome Reception and Poster Viewing

 

THURSDAY, NOVEMBER 13, 2025

08:00 AM – 09:00 AM Sponsored Breakfast Symposium
09:00 AM – 09:15 AM Break
09:15 AM – 09:45 AM Oral Presentations from Selected Abstracts

  • Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study ( Emma Guttman-Yassky, New York, USA)

  • The Interleukin (IL)1 family cytokines IL1, IL33 and IL36 differentially drive eosinophilic and neutrophilic inflammation in skin and lung in mice (Ellen Ezratty, Tarrytown, USA)

  • A Transcriptomic Atlas of Healthy Human Skin Links Regional Identity to Inflammatory Disease (Sahiti Marella, Ann Arbor, USA)
09:45 AM – 10:15 AM Innate Immunity in the Skin (Michel Gilliet, Lausanne, Switzerland)
10:15 AM – 10:45 AM The skin microbiome in immunodeficiency (Heidi Kong, Bethesda, MA, USA)
10:45 AM – 11:15 AM The tapestry of human prenatal immunity (Muzlifah Haniffa, Newcastle, United Kingdom)
11:15 AM – 11:45 AM Oral Presentations from Selected Abstracts

  • The intersection between skin aging and inflammatory skin diseases (Helen He, New York, USA)

  • Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide, in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From the Phase 3 ICONIC-LEAD Study (Mark Lebwohl, New York, USA)

  • Spatial Mapping of Autoimmune Pathogenesis in Hidradenitis Suppurativa Using Transcriptomics and High-resolution Multiplexed Imaging (Catherine Lu, New York, USA)
11:45 AM – 12:00 PM Break
12:00 PM – 01:30 PM Sponsored Lunch Symposium
01:30 PM – 01:45 PM Break
01:45 PM – 02:15 PM Harnessing metabolism to control skin inflammation (Rachael Clark, Boston, MA, USA)
02:15 PM – 02:45 PM Regulating Skin Inflammation (Michael Rosenblum, San Francisco, CA, USA)
02:45 PM – 03:15 PM Chronic Inflammation – What to Learn from Cutaneous Lymphomas (Patrick M. Brunner, New York, NY, USA)
03:15 PM – 03:45 PM Immune response patterns in inflammatory skin diseases (Kilian Eyerich, Freiburg, Germany)
03:45 PM – 04:15 PM Coffee Break
04:15 PM – 04:45 PM Cutaneous lupus (Joseph Merola, Dallas, TX, USA)
04:45 PM – 05:15 PM Inhibition of the JAK-STAT pathway in inflammatory diseases: Established therapy or still emerging hope? (Massimo Gadina, Washington, DC, USA)
05:15 PM – 05:45 PM Psoriasis: from TRMs to neutrophil pustulation (Johann Gudjonsson, Ann Arbor, MI, USA)
05:45 PM – 06:15 PM Novel insights of inducible skin-associated lymphoid tissue (iSALT) in inflammatory skin diseases (Kenji Kabashima, Kyoto, Japan)
06:15 PM – 06:30 PM Break
06:30 PM – 07:30 PM Sponsored Dinner Symposium
07:30 PM – 10:00 PM Poster Viewing and Scientific Networking

 

FRIDAY, NOVEMBER 14, 2025

08:00 AM – 09:00 AM Sponsored Breakfast Symposium
09:00 AM – 09:15 AM Break
09:15 AM – 10:15 AM Oral Presentations from Selected Abstracts

  • Serum Proteomic Analysis Distinguishes Early Mycosis Fungoides from Atopic Dermatitis (Yoni Sacknovitz, New York, USA)

  • Temtokibart, an IL-22RA1 Monoclonal Antibody, Broadly Downregulates Genes Associated with Activated Immune Pathways in Atopic Dermatitis: Results from a Phase 2b Trial Subgroup Analysis (Ester Del Duca, New York & Rome, USA & Italy)

  • Direct Comparison of Temtokibart and Dupilumab Using Single-Cell Characterization of Skin Biopsies Reveals Distinct Mechanisms of Action in Patients with Moderate to Severe Atopic Dermatitis (Christine Bangert, Vienna, Austria)

  • A humanized xenotransplant model reveals IgG4 and HSP70 as co-drivers of vitiligo and predicts clinical drug responses (Amos Gilhar, Haifa, Israel)

  • Single-Cell Transcriptomic Analysis Reveals Multicellular Drivers of Inflammation in Moderate-to-Severe Alopecia Areata (Benjamin Hu, New York, USA)

  • Skin and blood proteomic analysis of nemolizumab-treated patients demonstrates suppression of multiaxial inflammatory pathways and improved barrier protein signatures (Daniel Liu, New York, USA)
10:15 AM – 10:45 AM Neuronal Control of Cutaneous Inflammation (Dan Kaplan, Pittsburgh, PA, USA)
10:45 AM – 11:15 AM Sensing Inflammation in the Skin and Beyond (Brian Kim, New York, NY, USA)
11:15 AM – 11:45 AM Cutaneous Protease Signaling as a Driver of Disease and Comorbidity (Nicole Ward, Nashville, TN, USA)
11:45 AM – 12:00 PM Break
12:00 PM – 01:30 PM Sponsored Lunch Symposium
01:30 PM – 01:45 PM Break
01:45 PM – 02:15 PM Key Trends in Atopic Dermatitis: What Will the Next 5 Year Bring? (Alan Irvine, Dublin, Ireland)
02:15 PM – 02:45 PM Hair loss and systemic inflammation (Natasha Mesinkovska, Irvine, CA, USA)
02:45 PM – 03:15 PM Atopic Dermatitis & Alopecia Areata: Common Mechanisms and Targets (Emma Guttman-Yassky, New York, NY, USA)
03:15 PM – 03:45 PM Pemphigus vulgaris: More than one (genetic) disease (Eli Sprecher, Tel Aviv, Isreal)
03:45 PM – 04:15 PM Coffee Break
04:15 PM – 04:45 PM Is dupilumab a game-changer for bullous pemphigoid? (Dedee Murrell, Sydney, Australia)
04:45 PM – 05:15 PM Hidradenitis suppurativa (James G. Krueger, New York, NY, USA)
05:15 PM – 05:45 PM Vitiligo (John Harris, Worcester, MA, USA)
05:45 PM – 06:15 PM Early disease intervention and trained immunity (Curdin Conrad, MD, Switzerland)
06:15 PM – 06:30 PM Break
06:30 PM – 07:30 PM Sponsored Dinner Symposium

 

SATURDAY, NOVEMBER 15, 2025

08:30 AM – 09:30 AM Oral Presentations from Selected Abstracts

  • Brentuximab vedotin treatment reduces inflammatory gene expression by T and B cells in scleroderma skin, leading to reduced expression of pro-fibrotic markers (Laura Cooney, Ann Arbor, USA)

  • Early Versus Late Hidradenitis Suppurativa: Type 17 T-cell and B-cell Inflammation Precedes Dermal Tunnel and Tertiary Lymphoid Structure Formation (Jongeun Lee, New York, USA)

  • APG777, a Novel, Half-Life Extended Anti-IL-13 Antibody, Demonstrates Safety and Efficacy in Moderate-to-Severe Atopic Dermatitis: 16-Week Results From the Phase 2 APEX Study (Emma Guttman-Yassky, New York, USA)

  • A first-in-patient 18-week study of galvokimig, a multispecific antibody-based therapeutic targeting interleukin (IL)-13, IL-17A, and IL-17F in participants with moderate-to-severe atopic dermatitis (AD) (Hamish J. A. Hunter, Manchester, United Kingdom)
  • Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA) (Arash Mostaghimi, Boston, USA)
09:30 AM – 10:00 AM Seborrheic Dermatitis (Benjamin Ungar, New York, NY, USA)
10:00 AM – 10:15 AM Break
10:15 AM – 10:45 AM CART in Autoimmune Diseases (Christoph Ellebrecht, Philadelphia, PA, USA)
10:45 AM – 11:15 AM Spatial Imprint of Localised Disease Memory in Human Skin (Liv Eidsmo, Stockholm, Sweden)
11:15 AM – 11:45 AM Oral Presentations from Selected Abstracts

  • OX40 expression limits suppressive capacity of FOXP3+ T regulatory cells in pemphigus (Alberto Mesas-Fernández, Berlin, Germany)

  • TWEAK Signaling Drives the Transition from Psoriasis to Atopic Dermatitis–like Inflammation in Paradoxical Skin Reactions (Eran Cohen Barak, Afula, Israel)

  • Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results From APEX (Steven Fakharzadeh, Horsham, USA)
11:45 AM – 12:00 PM Break
12:00 PM – 01:00 PM Sponsored Symposium
01:00 PM Adjournment